Together, these findings support the use of calcitriol as a promising adjuvant agent to enhance the efficacy of current therapeutic regimens in HER2-positive breast cancer, particularly in tumors with low or absent ER expression or reduced responsiveness to endocrine therapy. Here, ERBB2 is linked to breast carcinoma.